Novel therapies for the treatment of CLL, MCL and FL
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
Integrating midostaurin into FLT3 positive AML treatment
iFCG: a promising new regimen for treating IGHV-mutated CLL
The next steps for TGR-1202 and targeting the gene c-Myc